HC Wainwright Has Pessimistic View of AGIO FY2026 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – HC Wainwright decreased their FY2026 earnings per share estimates for shares of Agios Pharmaceuticals in a report released on Tuesday, July 21st. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings per share of ($6.84) for the year, down from their previous estimate of ($6.77). HC Wainwright has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.33) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.60) EPS, FY2027 earnings at ($5.35) EPS, FY2028 earnings at ($4.15) EPS, FY2029 earnings at ($2.29) EPS and FY2030 earnings at $0.64 EPS.

AGIO has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Royal Bank Of Canada increased their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Truist Financial boosted their price target on Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. reduced their price target on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research report on Thursday, June 11th. Finally, Bank of America increased their price objective on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $42.78.

Agios Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ AGIO opened at $36.36 on Thursday. The firm’s 50-day moving average price is $33.90 and its 200-day moving average price is $30.67. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00. The company has a market cap of $2.16 billion, a PE ratio of -5.02 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.81) by $0.12. The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The business’s revenue for the quarter was up 137.7% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AGIO. T. Rowe Price Investment Management Inc. bought a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at approximately $25,000. Assetmark Inc. increased its stake in Agios Pharmaceuticals by 37.9% in the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 362 shares in the last quarter. NewEdge Advisors LLC bought a new stake in Agios Pharmaceuticals during the first quarter valued at about $40,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at about $49,000. Finally, Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals in the third quarter worth about $79,000.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Zacks highlighted Agios Pharmaceuticals as a potential earnings beat heading into Q2 results, suggesting expectations may be favorable ahead of the report. Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: HC Wainwright kept a bullish stance on Agios Pharmaceuticals (AGIO), maintaining a Buy rating and $52 target, which can reinforce investor confidence in the stock. HC Wainwright research note
• Neutral Sentiment: The same analyst firm made mixed EPS changes: it trimmed its FY2026 forecast slightly but raised estimates for FY2027 through FY2030, signaling a more constructive long-term outlook rather than a near-term catalyst. HC Wainwright earnings estimate updates
• Neutral Sentiment: Short-interest data showed 0 shares reported as shorted, which does not provide a meaningful bearish signal and is unlikely by itself to move the stock. Short interest update

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.